Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The PNOC031 regimen is a comprehensive treatment protocol developed by the Pacific Pediatric Neuro-Oncology Consortium (PNOC) and the University of California, San Francisco (UCSF) specifically for children with newly diagnosed Embryonal Tumor with Multilayered Rosettes (ETMR), a rare and aggressive pediatric brain tumor. The protocol utilizes a multi-modal approach that includes surgical resection followed by intensive induction chemotherapy, high-dose chemotherapy with autologous stem cell rescue, and focal radiation therapy. The chemotherapy component is a multi-agent regimen consisting of various antineoplastic drugs assigned based on physician choice and standard of care, typically including DNA alkylators, antimetabolites, and microtubule inhibitors to target the rapidly dividing tumor cells through multiple cytotoxic pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PNOC031 regimen.